Composition for Regulating Interfering Ribonucleic Acid Production

ChangeBridge: Patent Apps - Biotech (C12N)

Detected March 27th, 2026

Summary

The USPTO has published a new patent application (US20260085312A1) detailing compositions and methods for regulating interfering ribonucleic acid (miRNA) production. The application describes techniques to decrease the bioavailability of target biomolecules by degrading or inactivating their corresponding messenger RNA (mRNA).

View original document View source feed page

What changed

This document is a patent application (US20260085312A1) filed with the USPTO, describing novel compositions and methods for regulating the production of interfering ribonucleic acid (miRNA). The disclosed technology aims to upregulate miRNA sequences that are complementary to target messenger RNA (mRNA), leading to the degradation or inactivation of the mRNA. This process is intended to reduce the bioavailability of specific target biomolecules, such as CXCR2, which may help address afflictions associated with their expression.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in biotechnology and pharmaceutical research. Companies operating in the drug manufacturing and pharmaceutical sectors should monitor patent filings in this area for insights into emerging technologies and potential intellectual property landscapes. The filing date was April 23, 2025.

Source document (simplified)

← USPTO Patent Applications

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

Application US20260085312A1 Kind: A1 Mar 26, 2026

Inventors

Bradley G. THOMPSON

Abstract

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as CXCR2. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.